Canada's biosimilars market moves up a gear
This article was originally published in SRA
Executive Summary
There has been little action to date in the “subsequent entry biologics” field in Canada, with few submissions being filed and even fewer biologics patents being challenged. With the filing of the first SEB patent case, however, things are getting interesting, says Paula Bremner.